ERCC1 and astrocytoma (excluding glioblastoma): The stratified analyses of two histological subtypes indicated that the protective effect of EGFR rs730437 remained significant in both patients with astrocytoma and non-astrocytoma tumor subtypes (pDOM=0.018 and pDOM=0.014, respectively), whereas the risk effect of ERCC1 rs3212986 was more evident in patients with astrocytoma subtype (pDOM=0.002).